Company news

Heron Therapeutics, Inc. news in 2022

Heron Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF

December 28, 2022

Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference

November 20, 2022

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates

November 7, 2022

Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

October 31, 2022

Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)

September 15, 2022

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates

August 8, 2022

Heron Therapeutics Announces $76.5 Million Private Placement Financing

August 8, 2022

Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

August 1, 2022

Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability

June 29, 2022

Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty

June 13, 2022

Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

May 25, 2022

Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting

May 15, 2022

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates

May 8, 2022

Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

May 2, 2022

Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference

April 4, 2022

Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care

March 24, 2022

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain

March 16, 2022

Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

March 1, 2022

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates

February 27, 2022

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

February 21, 2022

Calls in 2022

Decks in 2022